Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Revenue (2016 - 2026)

Gyre Therapeutics has reported Revenue over the past 15 years, most recently at $37.2 million for Q4 2025.

  • Quarterly Revenue rose 33.45% to $37.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116.6 million through Dec 2025, up 10.24% year-over-year, with the annual reading at $116.6 million for FY2025, 10.24% up from the prior year.
  • Revenue was $37.2 million for Q4 2025 at Gyre Therapeutics, up from $30.6 million in the prior quarter.
  • Over five years, Revenue peaked at $101.5 million in Q4 2022 and troughed at $794000.0 in Q1 2022.
  • The 5-year median for Revenue is $26.1 million (2024), against an average of $24.7 million.
  • Year-over-year, Revenue tumbled 91.04% in 2021 and then soared 4059.67% in 2022.
  • A 5-year view of Revenue shows it stood at $2.4 million in 2021, then soared by 4059.67% to $101.5 million in 2022, then crashed by 73.25% to $27.1 million in 2023, then grew by 2.67% to $27.9 million in 2024, then surged by 33.45% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Revenue are $37.2 million (Q4 2025), $30.6 million (Q3 2025), and $26.8 million (Q2 2025).